Article

Postmarketing Surveillance for Oncology Drugs

Pamela Hallquist Viale

Susan Moore

toxins, adverse event, hazardous drugs
CJON 2008, 12(6), 877-886. DOI: 10.1188/08.CJON.877-886

Adverse effects of cancer therapies may occur more than three decades after drug administration. Continued vigilance in postmarketing use of oncology agents is necessary to accurately track adverse effects, update prescribing information, and alert healthcare providers in a timely manner. This article will define the processes involved in regulatory approval of oncology agents and discuss selected oncology drugs, labeling changes, and the role of oncology nurses in postmarketing surveillance by reviewing journal articles, governmental agency Web sites, federal regulatory documents, and pharmaceutical prescribing information. Oncology nurses administer and monitor cancer therapies in outpatient and inpatient settings and routinely assess patients for side effects of therapy; therefore, maintaining awareness of short- and long-term adverse effects after drug approval is important to patient safety. Nursing leadership should initiate, maintain, and manage an incident reporting system to effectively respond to changing needs. In addition, publication of case reports and articles on the emergence and management of postmarketing, treatment-related side effects in peer-reviewed nursing and medical journals may improve patient care and outcomes.

Jump to a section

    References

    Amgen Inc. (2008). Aranesp® (darbepoetin alfa) [Prescribing information]. Retrieved October 21, 2008, from http://www.aranesp.com/pdf/aranesp_pi.pdf
    AstraZeneca Pharmaceuticals LP. (2005). Iressa® (gefitinib) [Prescribing information]. Retrieved November 20, 2007, from http://www.astrazeneca-us.com/pi/iressa.pdf
    Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., et al. (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. Journal of Clinical Oncology, 23(34), 8580-8587.
    Camidge, R., Reigner, B., Cassidy, J., Grange, S., Abt, M., Weidekamm, E., et al. (2005). Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. Journal of Clinical Oncology, 23(21), 4719-4725.
    Centers for Medicare and Medicaid Services. (2007). Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Retrieved November 19, 2007, from http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203
    Cohen, M. H., Johnson, J. R., Chen, Y. F., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: Erlotinib (Tarceva®) tablets. Oncologist, 10(7), 461-466.
    Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003). FDA drug approval summary: Gefitinib (ZD1839) (Iressa®) tablets. Oncologist, 8(4), 303-306.
    Dagher, R., Cohen, M., Williams, G., Rothmann, M., Gobburu, J., Robbie, G., et al. (2002). Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Research, 8(10), 3034-3038.
    Dagher, R., Johnson, J., Williams, G., Keegan, P., & Pazdur, R. (2004). Accelerated approval of oncology products: A decade of experience. Journal of the National Cancer Institute, 96(20), 1500-1509.
    Dillman, R. O. (1999). Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Reviews, 18(4), 465-471.
    Fakih, M. G., & Lombardo, J. C. (2006). Bevacizumab-induced nasal septum perforation. Oncologist, 11(1), 85-86.
    Genentech Inc. (2005). Important drug warning: Herceptin®. Retrieved November 11, 2008, from http://www.gene.com/gene/products/information/pdf/herceptin-ddl.pdf
    Genentech Inc. (2008a). Avastin® (bevacizumab) [Prescribing information]. Retrieved October 21, 2008, from http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
    Genentech Inc. (2008b). Herceptin® (trastuzumab) [Prescribing information]. Retrieved November 7, 2008, from http://www.herceptin.com/hcp/safety.jsp
    Genentech Inc. (2008c). Tarceva® (erlotinib) [Prescribing information]. Retrieved October 21, 2008 from http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf
    Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia- Manero, G., Waddelow, T. A., et al. (2001). Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92(2), 406-413.
    Glusker, P., Recht, L., & Lane, B. (2006). Reversible posterior leukoencephalopathy syndrome and bevacizumab. New England Journal of Medicine, 354(9), 980-982.
    Gobel, B. H. (2007). Nursing considerations of bevacizumab use in multiple tumor types. Oncology Nursing Forum, 34(3), 693-701.
    Hampson, J. P., & Harvey, J. N. (2002). Postmarketing surveillance and black box warnings. JAMA, 288(8), 955-956.
    Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K. D., Schilcher, B., et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet, 362(9392), 1255-1260.
    ImClone Systems, Inc., & Bristol-Myers Squibb Company. (2008). Erbitux® (cetuximab) [Prescribing information]. Retrieved October 21, 2008, from http://packageinserts.bms.com/pi/pi_erbitux.pdf
    Inoue, A., Saijo, Y., Maemondo, M., Gomi, K., Tokue, Y., Kimura, Y., et al. (2003). Severe acute interstitial pneumonia and gefitinib. Lancet, 361(9352), 137-139.
    Keegan, P. (1999). FDA treads delicate line between safety and speed. Oncology (Williston Park), 13(1), 16.
    Khuri, F. R. (2007). Weighing the hazards of erythropoiesis stimulation in patients with cancer. New England Journal of Medicine, 356(24), 2445-2448.
    Ladewski, L. A., Belknap, S. M., Nebeker, J. R., Sartor, O., Lyons, A., Kuzel, T. C., et al. (2003). Dissemination of information on potentially fatal adverse rug reactions for cancer drugs from 2000 to 2002: First results from the research on adverse drug events and reports project. Journal of Clinical Oncology, 21(20), 3859-3866.
    Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287(17), 2215-2220.
    Lee, S. K. (2006). Re-examining our approach to the approval and use of new drugs. Canadian Medical Association Journal, 174(13), 1855.
    Mitka, M. (2003). Accelerated approval scrutinized: Confirmatory phase 4 studies on new drugs languish. JAMA, 289(24), 3227-3229.
    Murphy, S., & Roberts, R. (2006). "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. Journal of Allergy and Clinical Immunology, 117(1), 34-39.
    National Cancer Institute. (2008). FDA approval for bevacizumab. Retrieved October 21, 2008, from http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab
    Novartis Pharmaceuticals Corporation. (2008). Gleevec® [Prescribing information]. Retrieved October 21, 2008, from http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tata.pdf
    Ortho Biotech Products, L. P. (2008). Procrit® [Prescribing information]. Retrieved November 13, 2008, from http://www.procrit.com/procrit/impor_safe.html
    Ozcan, C., Wong, S. J., & Hari, P. (2006). Reversible posterior leukoencephalopathy syndrome and bevacizumab. New England Journal of Medicine, 354(9), 980-981.
    Rizzo, J. D., Somerfeld, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L. et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology, 26(1), 132-149.
    Roberts, T. G., Jr., & Chabner, B. A. (2004). Beyond fast track for drug approvals. New England Journal of Medicine, 351(5), 501-505.
    Roche Laboratories, Inc. (2008). Xeloda® [Prescribing information]. Retrieved October 21, 2008, from http://www.xeloda.com/hcp/xpert-resources-tools/xpert-resources.aspx
    Ruggiero, S., Gralow, J., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., et al. (2006). Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice, 2(1), 7-14.
    Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K., Kabbinavar, F., et al. (2007). Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute, 99(16), 1232-1239.
    Scharf, O., & Colevas, A. D. (2006). Adverse event reporting in publications compared with sponsor database for cancer clinical trials. Journal of Clinical Oncology, 24(24), 3933-3938.
    Schultz, W. B. (2007). Bolstering the FDA's drug-safety authority. New England Journal of Medicine, 357(22), 2217-2219.
    Trontell, A. (2004). Expecting the unexpected—Drug safety, pharmacovigilance, and the prepared mind. New England Journal of Medicine, 351(14), 1385-1387.
    U. S. Food and Drug Administration. (1998). Herceptin®. Retrieved November 11, 2008, from http://accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=trastuzumab
    U. S. Food and Drug Administration. (2000). Important drug warning: Herceptin®. Retrieved November 11, 2008, from http://www.fda.gov/medwatch/SAFETY/2000/hercep.htm
    U. S. Food and Drug Administration. (2001). May 2001 safety-related drug labeling changes. Retrieved November 20, 2007, from http://www.fda.gov/medwatch/safety/2001/may01.htm#mylota
    U. S. Food and Drug Administration. (2002). FDA Modernization Act of 1997. Retrieved November 20, 2007, from http://www.fda.gov/cdrh/modact/modern.html
    U. S. Food and Drug Administration. (2005a). Changes in Erbitux® package insert. Retrieved November 19, 2007, from http://www.ons.org/fda/documents/FDA91605.pdf
    U. S. Food and Drug Administration. (2005b). Detailed view: Safety labeling changes approved by FDA center for drug evaluation and research—November 2005. Retrieved November 14, 2007, from http://www.fda.gov/medWatch/safety/2005/nov05.htm
    U. S. Food and Drug Administration. (2006a). Fast track, accelerated approval and priority review. Retrieved November 11, 2008, from http://www.fda.gov/oashi/fast.html#priorityreview
    U. S. Food and Drug Administration. (2006b). 2006 safety alert: Gleevec® (imatinib mesylate). Retrieved January 6, 2008, from http://www.fda.gov/medwatch/safety/2006/Gleevec_DHCP_10-19-2006.htm
    U. S. Food and Drug Administration. (2007). List of approved oncology drugs and approved indications. Retrieved November 20, 2008, from http://www.accessdata.fda.gov/scripts/cder/onctools/druglist.cfm
    U. S. Food and Drug Administration. (2008a). Code of federal regulations title 21. Retrieved October 21, 2008, from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.56
    U. S. Food and Drug Administration. (2008b). MedWatch. Retrieved November 13, 2008, from http://www.fda.gov/medwatch
    U. S. Food and Drug Administration. (2008c). Safety alerts for human medical products: Bisphosphonates. Retrieved November 11, 2008, from http://www.fda.gov/medwatch/safety/2008/safety08.htm#Bisphosphonates
    Viale, P. H., Fung, A., & Zitella, L. (2005). Advanced colorectal cancer: Current treatment and nursing management with economic considerations. Clinical Journal of Oncology Nursing, 9(5), 541-552.
    Woo, S. B., Hellstein, J. W., & Kalmar, J. R. (2006). Narrative review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144(10), 753-761.
    Wood, A. J. (2000). Thrombotic thrombocytopenic purpura and clopidogrel: A need for new approaches to drug safety. New England Journal of Medicine, 342(24), 1824-1826.
    Wyeth Pharmaceuticals Inc. (2008). Mylotarg® (gemtuzumab ozogamacin) [Prescribing information]. Retrieved October 21, 2008, from http://www.wyeth.com/content/ShowLabeling.asp?id=119
    Wysowski, D. K., & Swartz, L. (2005). Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Archives of Internal Medicine, 165(12), 1363-1369.